Search
for
Sort by
Research 151–180 of 343
- Exploring the hair loss risk in glucagon‐like peptide‐1 agonists: Emerging concerns and clinical implications
- 74126 GLP-1RA Medications and Alopecia: Evaluating Risk Across Diabetic and Non-Diabetic Populations
- Metabolic syndrome – a new definition and management guidelines A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, “Club 30” Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons
- Treatment of insulin resistance with tirzepatide leading to improvement of hair loss
- Alopecia and Semaglutide: Connecting the Dots for Patient Safety
- Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome
- A Review of Metabolic Dysregulation in Lymphocytic Cicatricial Alopecia: Exploring the Connections and Therapeutic Implications
- EFLÚVIO TELÓGENO ASSOCIADO AO USO DE MEDICAMENTOS EMAGRECEDORES: MECANISMOS FISIOPATOLÓGICOS E EVIDÊNCIAS CLÍNICAS
- Maternal obesity and the metabolic syndrome in reproductive health: assessing incretin-based interventions
- CURRENT THERAPEUTIC APPROACHES IN THE MANAGEMENT OF POLYCYSTIC OVARY SYNDROME
- INDIVIDUALIZED TREATMENT OF POLYCYSTIC OVARY SYNDROME: A MANIFESTATION-GUIDED PRACTICAL APPROACH
- Editorial: Exploring innovative therapies for rare inflammatory skin diseases
- Methylene blue protects hair follicle stem cells from oxidative and metabolic stress to enhance hair regeneration
- Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review
- Abstracts from the 2024 WDS Forum - virtual option
- Antidiabetic Management Strategies for Treatment of Polycystic Ovarian Syndrome
- Polycystic Ovarian Disease: Current Insights and therapeutic Strategies
- Editor's Highlights — September 2024
- Blockbuster Weight-Loss Drugs Not Tied to Suicidality, Studies Show
- Women With Polycystic Ovary Syndrome: A Review of Susceptibility to Type 2 Diabetes
- Current aspects of polycystic ovary syndrome II: treatment of hyperandrogenism, insulin resistance and infertility
- Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
- Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database
- Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes
- Ann Robinson’s research reviews —12 May 2022
- Dermatologic Implications of Glycemic Control Medications for Patients with Type 2 Diabetes Mellitus
- Semaglutide as a Cornerstone Therapy in Obesity: Clinical and Pharmacological Insights
- Fast-tracked innovation: orforglipron approval under the FDA’s National Priority Voucher program
- Metabolic syndrome — a new definition and management guidelines
- Growth factors IGF-1 and KGF and adipose-derived stem cells promote migration and viability of primary human keratinocytes in an in vitro wound model